-- S&P500種株価指数とナスダック総合指数は、原油価格の下落を受け、テクノロジー株と一般消費関連株主導で過去最高値を更新した。 * ダウ工業株30種平均は、他のセクターの下落に伴い、下落した。 * ブルームバーグによると、イランは米国に対し新たな提案を行い、ドナルド・トランプ大統領は海上封鎖の継続を表明した。 * サプライマネジメント協会（ISM）が発表した4月の米国製造業景況指数は52.7で、ブルームバーグの調査で予測された53.2を下回った。 * アトランタ連邦準備銀行が発表した第2四半期の国内総生産（GDP）速報値は3.5%で、前回の3.7%から低下した。 * 6月限のWTI原油は2.91ドル下落し、1バレル102.15ドルで取引を終えた。一方、国際指標である7月限のブレント原油は1.88ドル下落し、1バレル108.62ドルで取引された。 * Cboeグローバル・マーケッツ（CBOE）の株価は、第1四半期の調整後利益と売上高の増加を受けて、S&P500指数構成銘柄の中で最大の上昇率となる9.1%上昇した。 * クロロックス（CLX）の株価は、2026年度の調整後1株当たり利益（EPS）見通しを引き下げたことを受けて、S&P500指数構成銘柄の中で最大の下落率となる9.7%下落した。
Related Articles
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.
$MRNA
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.
$GEHC
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of Lennox International Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target to $569 from $559, 21.4x our 2027 EPS estimate (down to $26.57 from $26.62; our 2026 estimate down to $24.14 from $24.51), near LII's three- and five-year historical forward averages of 21.9x and 20.6x, respectively. We think LII faces material near-term operational challenges from residential market softness, escalating tariff-driven cost inflation (~5% vs. prior ~2.5% guidance), and margin compression in its Home Comfort Solutions segment (390-bp decline to 13.3% in Q1). However, these concerns are substantially mitigated by the Building Climate Solutions segment's exceptional performance (38% revenue growth, 300-bp margin expansion to 19.7% in Q1), significantly improved operating cash flow ($16.1M vs. -$35.8M Y/Y) due to inventory normalization. We note an antitrust class action lawsuit, filed in March, alleging price-fixing among HVAC equipment manufacturers since January 2020, posing an additional risk to LII's financial and reputational standing.
$LII